Choosing the right Clinical Research Organization (CRO) is a critical decision for any pharmaceutical company. The selected CRO can significantly impact the success of your clinical trials and, ultimately, the time-to-market for your drug candidates. But with a sea of options, what should you focus on when evaluating a CRO? Here are key considerations to ensure you make the best choice:

Clinical research is a significant element of healthcare development, and the field of ophthalmology, specifically retinal disorders, is no exception. With the proliferation of ground-breaking research into retinal diseases like age-related macular degeneration (AMD), geographic atrophy, diabetic macular edema, and inherited retinal disorders, the need for expertise in this complex arena is ever-growing. That’s where we, as a retina-specialized Clinical Research Organization (CRO), enter the picture.

Matthias Steger, CEO at Endogena Therapeutics, reflected: “Getting this far in a remarkably short time is testament to the outstanding execution of our clinical team in collaboration with InFocus Clinical Research.

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company focused on gene therapies for retinal degenerative diseases, presented key results from its Phase 2 clinical trial, STARLIGHT, at the American Society of Retina Specialists (ASRS) annual meeting in Seattle last week. The trial evaluated the effects of their novel therapeutic, MCO-010, for patients with Stargardt disease, a condition currently lacking available treatments.